Peptide · Fact sheet
MOTS-c
Also known as MOTS-c peptide · mitochondrial ORF of 12S rRNA type-c
MOTS-c is an experimental mitochondrial-derived peptide studied for metabolism, exercise adaptation, and aging biology. It is not FDA approved, and FDA reports no identified human exposure data for drug products containing MOTS-c.
What is MOTS-c?
MOTS-c is a 16-amino-acid peptide encoded within mitochondrial DNA and produced as part of cellular stress and metabolic signaling.
Studies measuring natural MOTS-c levels in people are not treatment trials, and a synthetic analog such as CB4211 is not interchangeable with native MOTS-c.
Benefits & claims
Animal studies report effects on insulin sensitivity, metabolic stress, physical capacity, and age-related decline.
Those findings have fueled 'exercise mimetic' and longevity claims that go far beyond direct human intervention evidence.
What the evidence supports
- Animal studies report improved insulin sensitivity and physical capacity under selected experimental conditions.
- Human observational work shows associations with exercise and muscle measures, but association does not prove that administering MOTS-c produces a benefit.
Research areas
- Insulin sensitivity and metabolic regulation in animal models
- Exercise adaptation and physical capacity
- Age-related metabolic decline
- Muscle stress and mitochondrial signaling
- Metabolic disease and fatty-liver research
- Exercise and muscle-function biology
- Healthy-aging mechanisms
Dosage & frequency
No established human regimenMOTS-c evidence does not establish a human injection dose for metabolic health or exercise performance.
How to read these amounts
An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.
Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences
Formulations, interactions & practical context
Formulation differences
- A measured endogenous peptide level is not a treatment exposure.
- Studies of related investigational analogs cannot be assumed to apply to native MOTS-c.
Interactions & precautions
- Human interaction data are unestablished for native MOTS-c; findings for endogenous levels or related analogs cannot establish combination safety.
What is still unresolved
- Human dosing, pharmacokinetics, clinical efficacy, repeated-use safety, and interactions remain unestablished.
Side effects & risks
- FDA identifies potential immune reactions and complexities involving peptide impurities and active-ingredient characterization.
- There is no adequate human treatment dataset from which to estimate common, uncommon, or long-term harms.
- Unapproved products add identity, purity, sterility, strength, and labeling risks.
This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.
Clinical research
Mostly animal or lab researchMost treatment claims come from cells and animals. Human studies largely measure naturally circulating MOTS-c or response to exercise rather than test MOTS-c as a therapy.
Studies
Preclinical study in animal models; it does not establish a human treatment effect.
Study of naturally circulating peptide levels after exercise, not administration as a therapy.
Completed early trial of a MOTS-c analog; the registry does not show public results and the analog is not native MOTS-c.
Personal experiences
Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.
Explore 3 sourced accounts by reported effect.
Energy: reported experiences
Energy improved after several different exposures
A commenter reported little energy initially and more energy later, after a sequence involving SS-31, MOTS-c and NAD+.
Reported use in this account
- Product
- Product described as MOTS-c
- Amount
- 5 mg initially; later 3 mg, as reported
- Frequency
- Daily at the later 3 mg exposure; the earlier “5/2” notation is not expanded
- Route
- Not specified clearly
- Duration
- Two weeks initially and another two weeks later
Other exposures described: SS-31 before and between MOTS-c exposures; NAD+ added later
Multiple products and time effects prevent attribution to MOTS-c. The explanation about repairing mitochondria is unverified speculation.
Read the original accountMidday crashes during combined exposure
A 46-year-old woman described disappointing midday fatigue after about four weeks of MOTS-c while also using SLU-PP-332 and recently starting testosterone. A reply clarified that midday crashes predated these exposures.
Reported use in this account
- Product
- Product described as MOTS-c
- Amount
- 5 mg
- Frequency
- Every five days, explicitly clarified in a reply
- Route
- Not specified clearly
- Duration
- In week four
Other exposures described: SLU-PP-332; Testosterone gel started about 20 days earlier; Exercise and caffeine; Midday fatigue already present before these exposures
The pre-existing symptom and several concurrent products prevent attribution. Product contents and any mitochondrial explanation were not verified.
Read the original accountA modest energy lift during long workdays
A different commenter described a small pick-me-up during demanding workdays after about two weeks.
Reported use in this account
- Product
- Product described as MOTS-c
- Amount
- 2 mg in the morning, with a reported additional 1–2 mg on some long workdays
- Frequency
- Morning use and occasional midday use; number of use days per week not stated
- Route
- Not specified clearly
- Duration
- About two weeks
Other exposures described: Fasted workouts; Long workdays
Workload, exercise, other exposures and product contents were not controlled; there were no energy measurements.
Read the original accountApproval status
No MOTS-c drug product is FDA approved. FDA's current compounding safety summary states that it has not identified human exposure data for drug products containing MOTS-c.
Native MOTS-c remains preclinical as a treatment
Most treatment claims rely on animal or laboratory work. A related CB4211 analog reached Phase 1, but that analog is not interchangeable with native MOTS-c.
Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.
Open questions
- Whether administered MOTS-c produces any meaningful human metabolic or performance benefit
- Short- and long-term human safety
- How synthetic products compare with the naturally produced peptide
- Whether animal longevity or exercise findings translate to people
Summary
MOTS-c has preclinical metabolic and exercise findings. Controlled human outcome evidence remains missing.
Sources
Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.
- fdaFDA: safety risks for selected compounded bulk substances
FDA's current substance-specific summary of evidence gaps and potential safety risks.
- pubmedMOTS-c metabolism and insulin-sensitivity study
Preclinical study in animal models; it does not establish a human treatment effect.
- pubmedHuman exercise study of mitochondrial-derived peptides
Study of naturally circulating peptide levels after exercise, not administration as a therapy.
- clinical trialsClinicalTrials.gov: CB4211 Phase 1 study
Completed early trial of a MOTS-c analog; the registry does not show public results and the analog is not native MOTS-c.